MonaJuventa™ Nu and Telomere Length: The Science Behind Telomere Prime+
Every time a cell divides, the protective caps on the ends of its chromosomes — telomeres — get a little shorter. Eventually they get so short the cell stops dividing altogether. That process, repeated across trillions of cells over decades, is one of the most well-established biological signatures of aging. Telomere Prime+ now includes MonaJuventa™ Nu at 100mg, based on a randomized, double-blind, placebo-controlled human trial. Here's exactly what that trial found — and what it didn't.
The sections below walk through each of these findings in full, including the nuance that separates a genuinely rigorous result from a marketing headline.
What Telomeres Actually Tell You About Aging
Chronological age is just a number on a calendar. Biological age is a measure of accumulated cellular wear, and researchers increasingly use it alongside chronological age to help estimate health and disease risk — since two people of the same calendar age can show meaningfully different rates of cellular aging. Two of the most established ways to estimate it are:
- Leukocyte telomere length (LTL) — the length of the protective caps on white blood cell chromosomes. Shorter telomeres are associated with more cell divisions, more accumulated stress, and higher risk of age-related disease.
- DNA methylation age (DNAmAge) — sometimes called an "epigenetic clock." It's calculated from chemical modifications on specific stretches of DNA that shift in predictable patterns as we age, independent of telomere length.
A third marker, mitochondrial DNA copy number (mtDNAcn), tracks how much of the cellular machinery responsible for energy production a cell still has — it tends to decline with age, contributing to fatigue and reduced metabolic resilience.
Measuring all three in the same study is unusually thorough. That's what the MonaJuventa™ Nu trial did.
What Is MonaJuventa™ Nu?
MonaJuventa™ Nu is a natural extract of Monarda didyma — scarlet beebalm, a plant in the mint family — developed by Mibelle AG Biochemistry, a Swiss ingredient science company. It's included in Telomere Prime+ at 100mg, alongside the formula's existing actives: ac-11®, PQQ, spermidine (Puremidine®), sulforaphane (BroccoRaphanin®), and L-ergothioneine (MitoPrime®).
Inside the Study: Design and Participants
The trial (study S-1041) was conducted at Padova University Hospital in Italy, sponsored by Mibelle AG Biochemistry, and pre-registered with ClinicalTrials.gov (NCT05399966) — registration before a study begins is a meaningful transparency marker, since it means the researchers committed to their measured outcomes in advance rather than choosing what to report afterward.
It was a randomized, double-blind, placebo-controlled design — the gold standard for human nutrition research. Eighty-one adults aged 45–65 were enrolled, specifically drawn from a "susceptible working population" with self-reported high stress levels (shift workers, nurses, landscape and construction workers). Forty received 100mg of MonaJuventa™ Nu daily with lunch; forty-one received a matched 100mg maltodextrin placebo in identical capsules. Neither participants nor researchers knew who received which. The two groups were well matched on age, weight, and height at baseline, and the trial ran for 12 weeks (84 days).
Compliance was 100% in both groups, and there were no reported adverse events or gastrointestinal issues — a real, if modest, safety signal worth noting on its own.
What the Data Actually Showed
Telomere length
This is the headline finding, and it's worth reporting precisely rather than rounding up. Within the MonaJuventa™ Nu group, leukocyte telomere length increased, but that increase did not independently reach statistical significance on its own (p=0.053 — just above the conventional 0.05 threshold). In the placebo group, telomere length decreased, and that decline was clearly significant (p=0.0006). When the two groups were compared directly against each other, telomeres were significantly longer in the MonaJuventa™ Nu group than in the placebo group (p=0.004). In other words: telomere length moved in opposite directions between the two groups, and that gap was statistically real, even though the treatment group's own within-group change did not independently clear the significance threshold.
Epigenetic (DNA methylation) age
DNAmAge increased significantly in the placebo group (p<0.001) while remaining essentially unchanged in the MonaJuventa™ Nu group. Comparing the two groups directly, the placebo group's DNAmAge was significantly higher than the treatment group's after 12 weeks (p=0.016).
Mitochondrial DNA
Mitochondrial DNA copy number dropped significantly in the placebo group (p=0.002). In the MonaJuventa™ Nu group, the decline was smaller and did not reach statistical significance (p=0.17) — consistent with a protective, rather than reversing, effect on this particular marker.
Stress, sleep, and quality of life
Beyond the cellular markers, the study tracked salivary cortisol, self-reported quality of life (WHOQOL-BREF), and wearable-device data on physical activity and sleep. Cortisol dropped 25% in the MonaJuventa™ Nu group versus 18% in placebo. Quality-of-life scores rose significantly in the treatment group (p=0.0085), particularly in the physical-health domain, while the placebo group's scores slightly declined. Wearable data showed a significant increase in physical activity versus placebo, and a sleep-index improvement that reached a trend level (p=0.056) — just outside conventional significance, worth flagging rather than rounding into a firm claim.
The Cell Study Behind the Clinical Trial
A separate, earlier study (S-978) tested the mechanism more directly, in primary human fibroblasts pushed through six weeks of replicative aging in a lab dish. Cells treated with MonaJuventa™ Nu showed a significantly slower rate of telomere shortening than untreated controls (p<0.01), measured with a quantitative fluorescence in-situ hybridization technique. It's a cell-culture study, not a human outcome, so it can't stand on its own — but it gives the human trial's telomere finding a plausible mechanistic backstory, rather than leaving it as an isolated statistic.
What This Means — and Where the Limits Are
This is a genuinely well-designed study for the supplement category: randomized, double-blind, placebo-controlled, pre-registered, with three complementary biomarkers associated with biological aging measured at once and a supporting cell-culture mechanism. That combination is uncommon for a single botanical ingredient.
It also has real limits worth stating plainly, in keeping with how we evidence-grade every ingredient in our formulas. It's one trial, from one research group, sponsored by the ingredient's own manufacturer (Mibelle AG Biochemistry) — a completely standard arrangement in ingredient science, but a fact worth disclosing rather than omitting. The telomere-length result, specifically, was significant only in the between-group comparison, not in the treatment group's own before-and-after change. A single 12-week study also can't tell us whether these effects persist, grow, or plateau over years of use — that requires longer-term and independently replicated research.
What it does support is a genuinely promising result: a 12-week intervention that demonstrated a consistent pattern of favorable findings across three complementary biomarkers associated with biological aging, with no observed safety signal — the research base behind including MonaJuventa™ Nu in Telomere Prime+.
Frequently Asked Questions
Did MonaJuventa™ Nu lengthen telomeres in this study?
Participants receiving MonaJuventa™ Nu showed a numerical increase in leukocyte telomere length that approached, but did not reach, statistical significance (p=0.053). However, telomere length was significantly greater versus placebo at 12 weeks (p=0.004), suggesting a potential protective effect on telomere maintenance.
What's a normal rate of telomere shortening?
Telomere shortening rates vary by individual, lifestyle, and measurement method, which is part of why researchers compare a treatment group against a matched placebo group rather than relying on a single "normal" number.
Is MonaJuventa™ Nu the same thing as spermidine?
No. Spermidine (Puremidine®) supports autophagy through a separate pathway. MonaJuventa™ Nu is a Monarda didyma (scarlet beebalm) extract included in Telomere Prime+ as an additional, complementary active — not a substitute.
Were there any side effects reported in the trial?
No adverse events were reported in either the treatment or placebo group over the 12-week study, and compliance was 100% in both groups.
Telomere Prime+ is formulated with MonaJuventa™ Nu at the 100mg dose studied here, alongside ac-11®, PQQ, spermidine, sulforaphane, and L-ergothioneine. See the full label and formula.
Sources: Effects of MonaJuventa™ Nu on Epigenetic Age: A Randomized, Double-Blind, Placebo-Controlled Clinical Study (S-1041), Padova University Hospital / Mibelle AG Biochemistry, ClinicalTrials.gov NCT05399966. Effect of MonaJuventa™ Nu on Telomere Length in Human Fibroblasts (S-978), Mibelle AG Biochemistry. Final copy should be reviewed by legal/regulatory before publication.